Evidence map›Paper›PMID 36127090›Full record

ArticleBMJ open2022

Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI: protocol of the LIMA study - a multicentre prospective observational cohort study.

Liselore M Janssen, Britt B M Suelmann, Sjoerd G Elias, Markus H A Janse, Paul J van Diest, Elsken van der Wall, Kenneth G A Gilhuijs

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04223492 (Liquid Biopsies and Imaging in Breast Cancer), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04223492 nacompletednot on this map

Liquid Biopsies and Imaging in Breast Cancer

TypeinterventionalSponsorUMC UtrechtRan2019 to 2022Enrolled61ConditionsBreast CancerArmsLiquid biopsy, Multi-parametric MRI
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Liselore M JanssenImage Sciences Institute, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0003-1157-8978
Britt B M SuelmannDepartment of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
Sjoerd G EliasJulius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
Markus H A JanseImage Sciences Institute, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
Paul J van DiestDepartment of Pathology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
Elsken van der WallDepartment of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
Kenneth G A GilhuijsImage Sciences Institute, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands K.G.A.Gilhuijs@umcutrecht.nl.
Utrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe response to neoadjuvant chemotherapy (NAC) in breast cancer has important prognostic implications. Dynamic prediction of tumour regression by NAC may allow for adaption of the treatment plan before completion, or even before the start of treatment. Such predictions may help prevent overtreatment and related toxicity and correct for undertreatment with ineffective regimens. Current imaging methods are not able to fully predict the efficacy of NAC. To successfully improve response prediction, tumour biology and heterogeneity as well as treatment-induced changes have to be considered. In the LIMA study, multiparametric MRI will be combined with liquid biopsies. In addition to conventional clinical and pathological information, these methods may give complementary information at multiple time points during treatment.

aimTo combine multiparametric MRI and liquid biopsies in patients with breast cancer to predict residual cancer burden (RCB) after NAC, in adjunct to standard clinico-pathological information. Predictions will be made before the start of NAC, approximately halfway during treatment and after completion of NAC.

methodsIn this multicentre prospective observational study we aim to enrol 100 patients. Multiparametric MRI will be performed prior to NAC, approximately halfway and after completion of NAC. Liquid biopsies will be obtained immediately prior to every cycle of chemotherapy and after completion of NAC. The primary endpoint is RCB in the surgical resection specimen following NAC. Collected data will primarily be analysed using multivariable techniques such as penalised regression techniques. ETHICS AND DISSEMINATION: Medical Research Ethics Committee Utrecht has approved this study (NL67308.041.19). Informed consent will be obtained from each participant. All data are anonymised before publication. The findings of this study will be submitted to international peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04223492.

Indexed as

Breast NeoplasmsMultiparametric Magnetic Resonance ImagingFemaleHumansLiquid BiopsyMagnetic Resonance ImagingMulticenter Studies as TopicNeoadjuvant TherapyObservational Studies as TopicProspective StudiesTreatment OutcomeAdult oncologyBreast imagingBreast tumoursCHEMOTHERAPYMagnetic resonance imaging

Identifiers

PMID36127090
PMCPMC9490628
OpenAlexW4296808504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.